Post-Interleukin 1

(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
Zeile 3: Zeile 3:
 
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}}
 
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}}
 
{{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic  lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}}
 
{{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic  lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}}
 +
{{tp|p=32482538|t=ä. Propuesta de uso de anakinra en el distr�s respiratorio agudo secundario a COVID-19 |pdf=|usr=}}

Version vom 18. Juni 2020, 13:52 Uhr


32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32373790 2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
32482538 ä. Propuesta de uso de anakinra en el distr�s respiratorio agudo secundario a COVID-19

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis